Why the study?
Does the ergonovine test provide more precise recognition of coronary artery spasm than clinical data alone in patients with atypical chest pain?
Does the ergonovine test provide more precise recognition of coronary artery spasm than clinical data alone in patients with atypical chest pain?
Ergonovine testing does not provide more precise recognition of coronary artery spasm in patients with atypical chest pain than clinical data alone.
Ergonovine testing adds no diagnostic precision beyond clinical data in atypical chest pain; hypothesis-generating and should not change practice.
Thirty-five patients with atypical chest pain were given ergonovine maleate as a provocative test for coronary spasm. None of the patients had significant coronary atherosclerosis. The patients were divided into two groups based on clinical information available before ergonovine testing. Group 1 patients (n=13) had objective evidence of cardiac disease manifested by episodes of syncope, ventricular tachyarrhythmias, myocardial infarction, or transient ST segment shifts with chest pain. Group 2 patients had chest pain but no objective evidence of cardiac disease. The ergonovine test was positive in 11 of 13 patients in group 1. None of the 22 group 2 patients had a positive response to ergonovine. These data suggest that ergonovine testing does not allow for any more precise recognition of patients with atypical chest pain who have coronary artery spasm than do clinical data alone.
No takes yet. Share an insight, caveat, or question.
Joseph L. Gerry (1979) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: